Lower Costs, More Cures Act of 2019
Latest action · Dec 19, 2019 Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedDec 9, 2019
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Lower Costs, More Cures Act of 2019
This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs.
The bill generally
- limits payment amounts for drugs and biologics under Medicare medical services,
- reduces cost-sharing under the Medicare prescription drug benefit,
- modifies certain authorities and requirements under the Medicaid Drug Rebate Program,
- revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and
- establishes several reporting requirements for drug manufacturers with respect to drug prices.
Cosponsors 147
Members who signed on, in the order they did. Signatures ran from Dec 9, 2019 to Aug 18, 2020, with 111 there on the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-GA | A. Drew Ferguson IV | Original | Dec 9, 2019 |
| R-IL | Adam Kinzinger | Original | Dec 9, 2019 |
| R-NE | Adrian Smith | Original | Dec 9, 2019 |
| R-MO | Ann Wagner | Original | Dec 9, 2019 |
| R-OH | Anthony Gonzalez | Original | Dec 9, 2019 |
| R-TX | Bill Flores | Original | Dec 9, 2019 |
| R-MI | Bill Huizenga | Original | Dec 9, 2019 |
| R-OH | Bill Johnson | Original | Dec 9, 2019 |
| R-MO | Billy Long | Original | Dec 9, 2019 |
| R-MO | Blaine Luetkemeyer | Original | Dec 9, 2019 |
| R-OH | Bob Gibbs | Original | Dec 9, 2019 |
| R-OH | Brad R. Wenstrup | Original | Dec 9, 2019 |
| R-KY | Brett Guthrie | Original | Dec 9, 2019 |
| R-TX | Brian Babin | Original | Dec 9, 2019 |
| R-AR | Bruce Westerman | Original | Dec 9, 2019 |
Actions 4
Everything that happened, newest first.
- Dec 19, 2019Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
- Dec 10, 2019Referred to the Subcommittee on Health.
- Dec 9, 2019Introduced in House
- Dec 9, 2019Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Related bills 34
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 801 | A bill to amend titles XVIII and XIX of the Social Security Act to provide the Medicare Payment Advisory Commission and the Medicaid and CHIP Payment and Access Commission with access to certain drug payment information, including certain rebate informati | Related bill | Mar 14, 2019 |
| HR 938 | BLOCKING Act of 2019 | Related bill | May 2, 2019 |
| HR 965 | CREATES Act of 2019 | Related bill | May 16, 2019 |
| S 1227 | Prescription Pricing for the People Act of 2019 | Related bill | Jun 28, 2019 |
| HR 1264 | Payment Commission Data Act of 2019 | Related bill | Feb 15, 2019 |
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Administrative remedies
- Advisory bodies
- Appropriations
- Biological and life sciences
- Business records
- Cancer
- Chemistry
- Child health
- Civil actions and liability
- Competition and antitrust
- Congressional oversight
- Consumer affairs
- Corporate finance and management
- Cosmetics and personal care
- Department of Health and Human Services
- Digestive and metabolic diseases
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Executive agency funding and structure
- Federal Trade Commission (FTC)
- Food and Drug Administration (FDA)
- Fraud offenses and financial crimes
- Genetics
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Health information and medical records
- Health personnel
- Health programs administration and funding
- Health technology, devices, supplies
- Home and outpatient care
- Hospital care
- Immunology and vaccination
- Income tax deductions
- Income tax exclusion
- Inflation and prices
- Intellectual property
- Intergovernmental relations
- Judicial review and appeals
- Licensing and registrations
- Manufacturing
- Marketing and advertising
- Medicaid
- Medical education
- Medical research
- Medical tests and diagnostic methods
- Medicare
- Office of the U.S. Trade Representative
- Prescription drugs
- Product development and innovation
- Public participation and lobbying
- Research and development
- Retail and wholesale trades
- State and local government operations
- Trade agreements and negotiations
- User charges and fees
- Women's health
Text 1
Each version as it was printed, newest first.
- Dec 9, 2019Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov.